These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 33965340)

  • 21. A 4-week comparison of capillaroscopy changes, healing effect, and cost-effectiveness of botulinum toxin-A vs prostaglandin analog infusion in refractory digital ulcers in systemic sclerosis.
    Shenavandeh S; Sepaskhah M; Dehghani S; Nazarinia M
    Clin Rheumatol; 2022 Jan; 41(1):95-104. PubMed ID: 34471968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Botulinum toxin A treatment of Raynaud's phenomenon: a review.
    Iorio ML; Masden DL; Higgins JP
    Semin Arthritis Rheum; 2012 Feb; 41(4):599-603. PubMed ID: 21868066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.
    Ingegnoli F; Schioppo T; Allanore Y; Caporali R; Colaci M; Distler O; Furst DE; Hunzelmann N; Iannone F; Khanna D; Matucci-Cerinic M
    Semin Arthritis Rheum; 2019 Feb; 48(4):686-693. PubMed ID: 29706243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical relevance of Raynaud's phenomenon symptom characteristics in systemic sclerosis.
    Hughes M; Huang S; Pauling JD; Sabbagh M; Khanna D
    Clin Rheumatol; 2022 Oct; 41(10):3049-3054. PubMed ID: 35583625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Developing a core set of outcome measure domains to study Raynaud's phenomenon and digital ulcers in systemic sclerosis: Report from OMERACT 2020.
    Maltez N; Hughes M; Brown E; Hickey V; Park H; Shea B; Herrick AL; Pauling JD; Proudman S; Merkel PA
    Semin Arthritis Rheum; 2021 Jun; 51(3):640-643. PubMed ID: 33947582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of botulinum toxin in treating scleroderma-associated raynaud's phenomenon: a systematic review and meta-analysis.
    Elrosasy A; Abo Zeid M; Cadri S; Fahmy BM; Elzeftawy MA; Mohammed F; Ramadan A
    Arch Dermatol Res; 2024 Apr; 316(5):122. PubMed ID: 38630277
    [No Abstract]   [Full Text] [Related]  

  • 27. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of botulinum toxin type A injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis.
    Jokar MH; Baghbani B; Geraylow KR; Shariati J; Mehrad-Majd H; Mirfeizi Z; Hashemzadeh K
    Reumatologia; 2022; 60(6):392-398. PubMed ID: 36683833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of cutaneous vascular complications in systemic scleroderma: experience from the German network.
    Herrgott I; Riemekasten G; Hunzelmann N; Sunderkötter C
    Rheumatol Int; 2008 Aug; 28(10):1023-9. PubMed ID: 18320192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
    Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
    J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy of beraprost sodium on Raynaud's phenomenon in patients with systemic sclerosis].
    Kaburaki J; Kuwana M; Akizuki M; Takano M; Tojo T
    Nihon Rinsho Meneki Gakkai Kaishi; 1995 Feb; 18(1):29-35. PubMed ID: 7553036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Use of Botulinum Toxin in Raynaud Phenomenon: A Comprehensive Literature Review.
    Lawson O; Sisti A; Konofaos P
    Ann Plast Surg; 2023 Jul; 91(1):159-186. PubMed ID: 37450876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis.
    Meyrick Thomas RH; Rademaker M; Grimes SM; MacKay A; Kovacs IB; Cook ED; Bowcock SM; Kirby JD
    Br J Dermatol; 1987 Aug; 117(2):237-41. PubMed ID: 3307894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Raynaud's phenomenon-an update on diagnosis, classification and management.
    Pauling JD; Hughes M; Pope JE
    Clin Rheumatol; 2019 Dec; 38(12):3317-3330. PubMed ID: 31420815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients.
    Rosato E; Borghese F; Pisarri S; Salsano F
    Clin Rheumatol; 2009 Dec; 28(12):1379-84. PubMed ID: 19690939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
    Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel Combined Approach for Digital Necrosis Secondary to Raynaud's Phenomenon.
    Vegas DH; Fabiani MA; Gonzalez-Urquijo M; Bignotti A; Seré I; Salvadores P
    Vasc Endovascular Surg; 2021 Oct; 55(7):766-771. PubMed ID: 33866879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of Raynaud's phenomenon and digital ulcers in systemic sclerosis.
    Botzoris V; Drosos AA
    Joint Bone Spine; 2011 Jul; 78(4):341-6. PubMed ID: 21183379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study.
    Sambo P; Amico D; Giacomelli R; Matucci-Cerinic M; Salsano F; Valentini G; Gabrielli A
    J Rheumatol; 2001 Oct; 28(10):2257-62. PubMed ID: 11669166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.